Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Tysabri Study Participants To Undergo MRI, Physical In Search For Cause Of Adverse Events

This article was originally published in The Pink Sheet Daily

Executive Summary

Biogen Idec and Elan are suspending Tysabri clinical trials and conducting MRIs and physicals on trial participants as part of their voluntary marketing suspension of the multiple sclerosis therapy, the companies said

You may also be interested in...



FDA Re-Approves Tysabri, Recommends Second-Line Use

Biogen Idec expects to re-launch the multiple sclerosis therapy in July.

FDA Re-Approves Tysabri, Recommends Second-Line Use

Biogen Idec expects to re-launch the multiple sclerosis therapy in July.

Copaxone Reaches MS Market Share High Following Tysabri Withdrawal

Teva’s multiple sclerosis therapy glatiramer gained the leading market position in both total and new prescriptions in March, the company says. Copaxone’s gains followed Biogen Idec/Elan’s marketing suspension of the competing MS therapy Tysabri and the addition of a liver damage warning to Biogen’s Avonex.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS061649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel